News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AnGes MG Inc. Enters Into the Definitive Agreement With Mitsubishi Tanabe Pharma Corporation for Exclusive Marketing Rights of Collategene® in the United States


10/24/2012 8:44:31 AM

TOKYO, Oct. 24, 2012 (GLOBE NEWSWIRE) -- AnGes MG Inc. ("AnGes") announced today that the company has entered into a definitive agreement with Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, President & CEO, Michihiro Tsuchiya, "MTPC") for the exclusive marketing rights of Collategene® (DNA Plasmid with HGF gene) as a treatment for Peripheral Arterial Disease (PAD) in the United States.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES